<DOC>
	<DOCNO>NCT02104947</DOCNO>
	<brief_summary>Evaluate reversal anticoagulant effect dabigatran IV administration 5.0g idarucizumab patient treat dabigatran etexilate uncontrolled bleed require emergency surgery procedure .</brief_summary>
	<brief_title>Reversal Dabigatran Anticoagulant Effect With Idarucizumab</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Inclusion criterion : Group A ( Bleeding patient ) Overt bleed judged physician require reversal agent Currently take dabigatran etexilate At least 18 year age Written inform consent Group B ( Patients take dabigatran may bleed , require emergency surgery procedure condition bleed Condition require emergency surgery invasive procedure adequate hemostasis require . Emergency define within follow 8 hour . Current treatment dabigatran At least 18 year age Written Informed consent . Exclusion criterion : Group A ( Bleeding Patients ) Patients minor bleeds ( epistaxis , hematuria ) manage standard supportive care . Patients clinical sign bleed Contraindications study medication include know hypersensitivity drug excipients . Group B ( Patients require emergency surgery procedure ) A surgery procedure elective risk uncontrolled unmanageable bleeding low . Contraindications study medication include know hypersensitivity drug excipients ( subject hereditary fructose intolerance may react sorbitol ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>